Compare Novartis AG (NVS) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.71 (market cap $2.06B). The key difference: Novartis AG is far larger — about 130.4× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Novartis AG pays a 3.31% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| NVS | TMF | |
|---|---|---|
Market Cap | $268.57B | $2.06B |
Volume | 1,532,573 | 10,528,006 |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $44.14 |
52-Week Low | $121.80 | $25.19 |
Typical Hold Time | 82 Days | 28 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) trades at $25.23, down 0.51% with elevated trading volume of 5.2 million shares. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oversold RSI readings suggest potential for near-term bounce. The ETF saw increased investor interest amid bond market volatility.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risk. Current oversold conditions may present tactical opportunities, though the bearish technical structure and interest rate sensitivity require careful risk management for investors seeking directional bond exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
